Optimisation studies in oncology are crucial for understanding dosages and treatment durations post-drug approval. Successful research, especially in immunotherapy, is highlighted from various countries, with India emerging as a potential research hub. Dr Goldstein emphasises practical oncology care rather than just promoting new drugs. A strong call for critical thinking about data and costs in oncology encourages professionals to question traditional practices.